📁Pharma Team / Shared drive
18 documents across 5 categories
HTA submissions
4 docsDOC
NICE STA Submission Plan — Veltarix
Submission deadline 2026-09-01. ICER threshold strategy assumes £28k/QALY base case. 4 blocker gaps remaining, biggest is long-term durability extrapolation (14mo to close).
2w ago·HTA Lead, UK
DOC
Evidence Dossier Index — Global Master
47 evidence assets mapped across NICE, G-BA, HAS, CADTH, JCA. Module 4 economic models versioned in /econ/v6/.
3w ago·Global Value & Access
DOC
HTA Evidence Gap Report — Q2 2026
Three blocker gaps remain across the global submission portfolio: ITC vs SoC, long-term durability, renal subgroup. Combined estimated time to close: 18 months.
3w ago·HEOR Director
DOC
2024 G-BA Dossier — Module 4 Lessons Learned
IQWiG flagged comparator selection (docetaxel) as inappropriate vs G-BA-defined ZVT (pembrolizumab monotherapy). Benefit assessment downgraded to 'non-quantifiable'.
Nov 4, 2024·HTA Lead, DACH